Monitor for clinical trial readouts from the DReAMzz dose optimisation study for IHL-42X and any regulatory updates for PSX-001, which would provide more material catalysts than this research coverage initiation.
Price Chart
Executive Summary
Incannex Healthcare announced that Alliance Global Partners (AGP) has initiated equity research coverage with a BUY rating and an $18.00 price target. The coverage highlights the company's lead programs IHL-42X (obstructive sleep apnoea) and PSX-001 (generalized anxiety disorder). This is a routine disclosure with no new financial data or operational catalysts.
Key Facts
- Alliance Global Partners initiated equity research coverage on Incannex Healthcare with a BUY rating
- Price target set at $18.00 per share by analyst James Molloy
- Report dated June 8, 2026, covers IHL-42X and PSX-001 programs
- AGP has received compensation from Incannex for providing investment banking services
Financial Impact
No financial figures reported; analyst price target of $18.00 per share vs. current market cap of $41M
Risk Factors
- Analyst coverage does not guarantee increased investor awareness or liquidity
- AGP has received investment banking compensation from Incannex, creating potential conflict of interest
- Clinical-stage biotech with no approved products carries inherent development and regulatory risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-066526 |
| Document: ea029393401ex99-1.htm | 0001213900-26-066526 |
| Document: 0001213900-26-066526-index-headers.html | 0001213900-26-066526 |
| Document: 0001213900-26-066526-index.html | 0001213900-26-066526 |
| Document: 0001213900-26-066526.txt | 0001213900-26-066526 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 6w ago | 8-K | $3.23 $3.18 | ▼ −1.55% | ▼ −3.49% | $2.65 (−17.96%) |
Aug 25, 2026 9w ago | 8-K | $3.75 $3.45 | ▼ −8.13% | ▼ −9.11% | $2.65 (−29.33%) |
Aug 11, 2026 11w ago | 8-K | $3.20 $3.23 | ▲ +0.94% | ▲ +2.00% | $2.65 (−17.19%) |
Jul 23, 2026 13w ago | Press Release | $3.16 $3.62 | ▲ +14.56% | ▲ +11.25% | $2.65 (−16.14%) |
Jul 23, 2026 13w ago | 8-K | $3.16 $3.62 | ▲ +14.56% | ▲ +11.25% | $2.65 (−16.14%) |
Jun 10, 2026 19w ago | Press Release | $3.91 $3.37 | ▼ −13.81% | ▼ −17.43% | $2.65 (−32.23%) |
Jun 10, 2026 19w ago | 8-K | $3.91 $3.37 | ▼ −13.81% | ▼ −17.43% | $2.65 (−32.23%) |
Jun 9, 2026 20w ago | 8-K | $3.67 $3.71 | ▲ +1.09% | ▼ −0.36% | $2.65 (−27.79%) |
May 14, 2026 23w ago | Press Release | $3.88 $3.83 | ▼ −1.29% | ▼ −0.43% | $2.65 (−31.70%) |
May 14, 2026 23w ago | 8-K | $3.88 $3.83 | ▼ −1.29% | ▼ −0.43% | $2.65 (−31.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers